Literature DB >> 19847608

Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration.

Koko Saito1, Teiko Yamamoto, Daijiro Tsuchiya, Ryo Kawasaki, Shion Haneda, Hidetoshi Yamashita.   

Abstract

PURPOSE: To evaluate the benefit of the combination of a single sub-Tenon injection of triamcinolone acetonide (STTA) with photodynamic therapy (PDT) for the treatment of age-related macular degeneration (AMD) in Japanese patients.
METHODS: The medical records of 111 eyes of 111 patients were reviewed retrospectively. Forty-five eyes underwent combined treatment with STTA and PDT, and 66 eyes underwent PDT alone. Time to vision loss, defined as a change of 0.3 or more logarithm of minimum angle of resolution (logMAR) units, and time to retreatment were evaluated using the Kaplan-Meier survival analyses. Cox regression models were used to estimate the hazard ratios for those end points to investigate clinical risk characteristics.
RESULTS: Patients who underwent combined STTA with PDT had a significantly lower risk of retreatment than did those who underwent PDT alone (hazard ratio, 0.59; 95% confidence interval, 0.36-0.99). This beneficial association was found only in patients without polypoidal choroidal vasculopathy (PCV) lesions. However, combined treatment with STTA and PDT had no beneficial effect in reducing visual loss when compared with treatment with PDT alone.
CONCLUSION: Combined treatment with STTA and PDT had a beneficial effect in reducing retreatment of AMD in Japanese patients. Those who had PCV lesions did not benefit from this additional treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19847608     DOI: 10.1007/s10384-009-0703-6

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  30 in total

1.  Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration.

Authors:  E Rechtman; R P Danis; L M Pratt; A Harris
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

2.  [Criteria for diagnosis of polypoidal choroidal vasculopathy].

Authors: 
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2005-07

3.  Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.

Authors:  Albert J Augustin; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2006-04       Impact factor: 5.258

4.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

5.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

6.  Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2005-02       Impact factor: 12.079

7.  Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

8.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Yoko Matsumoto; Shiho Kashiwakura; Kyoko Fujita; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

9.  Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

Review 10.  Photodynamic therapy in macular diseases of asian populations: when East meets West.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Yasuo Tano; David T L Liu; Kenneth K W Li; Dennis S C Lam
Journal:  Jpn J Ophthalmol       Date:  2006 Mar-Apr       Impact factor: 2.211

View more
  5 in total

1.  One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.

Authors:  Yukari Shirakata; Chieko Shiragami; Ayana Yamashita; Eri Nitta; Atsushi Fujiwara; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2012-09-19       Impact factor: 2.447

2.  Utility values in Japanese patients with exudative age-related macular degeneration.

Authors:  Yasuo Yanagi; Takashi Ueta; Ryo Obata; Aya Iriyama; Takashi Fukuda; Hideki Hashimoto
Journal:  Jpn J Ophthalmol       Date:  2011-02-18       Impact factor: 2.447

3.  Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration.

Authors:  Chikako Yoshizawa; Wataru Saito; Shigeki Hirose; Hirokuni Kitamei; Kousuke Noda; Susumu Ishida
Journal:  Jpn J Ophthalmol       Date:  2012-10-24       Impact factor: 2.447

Review 4.  Polypoidal choroidal vasculopathy: An update on current management and review of literature.

Authors:  Amit Harishchandra Palkar; Vikas Khetan
Journal:  Taiwan J Ophthalmol       Date:  2019 Apr-Jun

5.  Systemic steroids as an aid to the management of Idiopathic Polypoidal Choroidal Vasculopathy (IPCV): A descriptive analysis.

Authors:  Aditya Sudhalkar; Divya Balakrishnan; Subhadra Jalali; Raja Narayanan
Journal:  Saudi J Ophthalmol       Date:  2015-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.